Eiger BioPharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.03.22	Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022 (PR Newswire)
10.03.22	Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (PR Newswire)
24.02.22	Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10 (PR Newswire)
06.01.22	Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones (PR Newswire)
03.01.22	Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference (PR Newswire)
21.12.21	Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (PR Newswire)
15.12.21	Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients (PR Newswire)
01.12.21	Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting (PR Newswire)
10.11.21	Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor Conferences (PR Newswire)
04.11.21	Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
02.11.21	Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15 (PR Newswire)
01.11.21	Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV (PR Newswire)
21.10.21	Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 Financial Results and Business Update on Thursday, November 4 (PR Newswire)
01.10.21	Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (PR Newswire)
21.09.21	Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer (PR Newswire)
20.09.21	Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients (PR Newswire)
01.09.21	Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences (PR Newswire)
05.08.21	Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
03.08.21	Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences (PR Newswire)
07.07.21	Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference (PR Newswire)
06.07.21	Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients (PR Newswire)
02.07.21	Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (PR Newswire)
29.06.21	Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib) (PR Newswire)
28.06.21	Eiger Announces Positive Phase 2 Results Of Avexitide In Congenital Hyperinsulinism (RTTNews)
28.06.21	Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session (PR Newswire)
23.11.20	Pre-market Movers In Healthcare Sector: EIGR, SNOA, REGN, TTNP, OCGN… (RTTNews)
22.11.20	Week Ahead In Pharma: EIGR Scripts History With Progeria Treatment, LQDA, RYTM Await FDA Decision (RTTNews)
15.11.20	Week Ahead In Pharma: FDA Decisions, Data Readouts (ADMP, EIGR, KZIA, AVRO…) (RTTNews)
02.11.20	Will Eiger's Zokinvy Make History To Become First-ever Progeria Treatment? (RTTNews)
26.10.20	Biotech Stocks Facing FDA Decision In November 2020 (RTTNews)
16.10.20	SNY/TBIO Move COVID-19 Vaccine Into Clinic, AVXL's PDD Study Promising, EIGR On Watch (RTTNews)
15.10.20	Stock Alert: Eiger BioPharma Climbs 8% (RTTNews)
28.09.20	Stock Alert: Eiger BioPharmaceuticals Down 15% (RTTNews)
11.11.19	What Awaits ASMB, DRRX, EIGR At The Liver Meeting? (RTTNews)
09.07.19	5 Top Gainers In Healthcare Sector (SOLY, ADVM, BLFS...) (RTTNews)
17.10.18	CERS Boosts Revenue Outlook, KOOL Hands Out Pink Slips, EIGR'S UTLRA Study Fails (RTTNews)
14.08.18	MBIO & Bubble Boy Disease Gene Therapy, Busy Months Ahead For EIGR, UMRX (RTTNews)
19.06.18	InventHelp Inventor Develops CARRY ON (DPH-280) (PR Newswire)
04.06.18	Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ (PR Newswire)
30.05.18	Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference (PR Newswire)
18.05.18	EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens (RTTNews)
16.05.18	Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) (PR Newswire)
16.05.18	Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals (PR Newswire)
11.05.18	Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results (PR Newswire)
17.04.18	Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver... (PR Newswire)
08.04.18	An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…) (RTTNews)
04.04.18	PMC Increases Throughput Efficiency and Job Quality with Rethink Robotics' Sawyer (PR Newswire)
02.04.18	Eiger BioPharmaceuticals to Participate in Conferences in April (PR Newswire)
26.03.18	Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia (PR Newswire)
21.03.18	Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Eiger BioPharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten